WHO Issues Concern Over Severe Shortage of Obesity Jabs

Fewer than a tenth of people eligible to benefit from obesity jabs including Wegovy have access to them, caution the World Health Organization as it issues its first guidance on the medications.

Considering more than one billion individuals worldwide now classified as obese, it is urging increased and just access to these injectable treatments.

Per forecasts, in excess of 2,000,000,000 will be obese by 2030 if no action is taken.

"The latest guidance recognises that excess weight is a lifelong illness that can be managed with comprehensive and continuous treatment," stated the agency's head Tedros Adhanom Ghebreyesus.

Substantial prices, constrained manufacturing, and logistical bottlenecks are major obstacles to universal access to the treatments that can assist patients in reducing significant body mass, says the agency.

Weight-Loss Drug Shortage

Despite the current most favorable case, the supply of GLP-1 therapies could only cover around 100 million people – under 10% of those who need them, as stated by the health organization.

The advice calls on governments and firms to expand access, through strategies including licensing agreements.

A patent on the active ingredient – the main component of a leading brand – is scheduled to end in multiple nations in 2026.

How Weight-Loss Injections Function

These medications replicate a body's own hormone to delay gastric emptying, suppress the appetite and boost the sense of being full so individuals consume fewer calories.

People typically start to lose weight after several weeks of starting on the once-weekly jabs.

Research points to people may regain a significant portion a year later of halting the treatment, when their normal hunger resume.

Being above a healthy weight raises your chance for developing diseases, including type 2 diabetes, heart disease, brain attack, and certain cancers.

Excess weight impacts individuals in every country and was associated with over three and a half million deaths worldwide in 2024, according to the WHO.